StockWatch
·

Premier Energies Ltd Q2 FY27 Results

PREMIERENEQ2 FY27 Results
Filing
Result:Steady· Market: Down#Margin squeeze#Broad based

Outlook: Optimistic · Guidance: Cut

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue2.6K6.9%43.3%
Total Income2.7K5.9%38.2%
Expenditure2.1K8.8%41.3%
PBT601.123.0%28.6%
Net Profit462.392.0%30.8%
OPM27.96%1.05pp2.57pp
NPM17.41%1.41pp0.99pp
EPS10.242.0%29.8%
View full financials

Revenue grew a strong 43.3% YoY on core solar cell/module demand with PAT up 30.8%, but OPM compressed to 27.96% from 30.53% and NPM to 17.41% from 18.4%, so margin squeeze caps this just above an in-line quarter.

PREMIERENE · Q2 FY27 · THE VERDICT

Strong Order Book, Stalling Profit Momentum

Revenue surged 43% YoY and PAT grew 31%, but the quarter reveals a profit crisis hiding in the headline: QoQ PAT fell 2% despite 7% revenue growth, capex guidance was slashed 53%, and margins are compressing under commodity pressure. The long-term growth story remains intact; near-term execution is deteriorating.

11 Nov 2026 · 6 min read
Revenue (YoY)

₹2,632 Cr

+43.3%

Revenue (QoQ)

+6.9%

Sequential slowdown

PAT (YoY)

₹462 Cr

+30.8%

PAT (QoQ)

-2.0%

Profit declined

The year-on-year numbers invite celebration — revenue up 43%, PAT up 31%, order book raised to ₹16,260 Cr from ₹15,000 Cr. But flip to the quarter-on-quarter picture and the story inverts. Revenue grew 6.9% sequentially, yet net profit fell 2%. That gap — strong topline growth with stalling profit — is the quarter's central tension.

Where the profit drain is coming from

Operating margin compressed to 28.0% from the prior year's 29.0% — a 100 bps headwind against the 29-30% guidance band. The solar segment EBITDA margin of 29.3% came in line with guidance, but transformer margin collapsed from 22% in Q1 to 12% in Q2 as commodity inflation (steel, copper, aluminum) hit BOM costs. Management expects normalization to 15%, but near-term margin recovery is uncertain. More troubling: despite bringing 5.6 GW of new module capacity and 7 GW of cell capacity into the system, the company is not achieving operating leverage. Revenue scaling faster than profit suggests mix dilution (higher-volume, lower-margin modules consuming cells; inventory buildup of ₹1.5% of sales adding working capital drag). The cell line ramp is ramping — but not yet monetizing.

Q2 FY27 growth rates
-7.4411.2930.0148.7443.3Revenue YoY30.8PAT YoY6.9Revenue QoQ-2PAT QoQ
YoY growth hides sequential profit decline. Operating leverage from ₹15,600+ Cr capex spent on new cell/module capacity is not flowing through to earnings.
Management claims vs. reality

Q2 revenue ₹2,656 Cr, up 38.2% YoY

What was delivered

₹2,632 Cr, up 43.3% YoY

Verdict

Overstated (mgmt revenue figure cited 1% high; actual YoY outpaced guidance)

PAT ₹462 Cr, up 30.8% YoY

What was delivered

₹462.4 Cr, up 30.8% YoY

Verdict

Supported exactly

Solar EBITDA margin 29.3%, PAT margin 17.9%

What was delivered

Company OPM 28.0%, NPM 17.4%; segment-level margin slightly higher

Verdict

Supported

Order book ₹16,260 Cr, up from ₹15,000 Cr prior

What was delivered

Confirmed; ₹1,260 Cr (+8.4%) net increase

Verdict

Supported

7 GW TOPCon cell line 70% utilization by March FY27

What was delivered

Cell line commissioned, trial runs underway, commercial production starting Nov 2026

Verdict

Supported (on track for 70% target)

QoQ PAT stable / modest growth

What was delivered

QoQ PAT -2.0%

Verdict

Contradicted (sequential profit declined)

What shifted on this call — three critical moves

1. Order book raised. Premier upgraded order book from ₹15,000 Cr to ₹16,260 Cr (+₹1,260 Cr), driven by ₹4,001 Cr in new cell and module wins in Q2 alone. This is substantive. The company is winning market share despite DCR module pricing collapsing to ₹21-22 per watt in a commoditized market. Long-term visibility improves. 2. Capex guidance slashed 53%. FY27 capex revised from ₹5,100 Cr to ₹2,400 Cr. This is the quarter's most alarming signal. Management attributed the cut to bulk of cell and module capacity already live, with "marginal leftovers" remaining — but cutting capex by ₹2,700 Cr contradicts the urgency of the 10 GW ingot-wafer roadmap (Phase 1: 5 GW by Dec 2027, Phase 2: +5 GW by June 2028) that was just announced. Either capital is tighter than the bullish narrative suggests, or the capex plan itself has been downgraded. Either interpretation signals caution. 3. Transformer margin under pressure; ingot-wafer announced. Transformer EBITDA margin fell from 22% in Q1 to 12% in Q2 due to commodity cost inflation. Management guided normalization to 15% — implying Q2 was an anomaly, not a trend. But 10 percentage points of margin swing in one quarter raises questions about cost control. In parallel, the ingot-wafer plan was unveiled: 10 GW capacity by June 2028. This is a growth lever, but it requires capex — which just got cut. The mismatch is stark.

Bull-bear ledger
  • Order book ₹16,260 Cr; Q2 wins ₹4,001 Cr (robust demand)

  • 7 GW cell line on track; commercial production Nov 2026

  • 10 GW ingot-wafer capacity plan (5 GW Dec 2027, +5 GW June 2028)

  • Transformer 4 GVA commissioned; trebling target over 3 years

  • BESS operationalization Q2 FY28; government policy support likely

  • QoQ PAT -2.0% despite 6.9% revenue growth

  • Capex guidance cut ₹2,700 Cr (53% reduction from ₹5,100 Cr)

  • OPM 28.0% vs. 29-30% guidance; 100 bps compression YoY

  • Transformer margin Q2 12% vs. Q1 22% (commodity inflation)

  • Inventory buildup ₹1.5% of sales; working capital drag

  • DCR module pricing ₹21-22/watt in competitive market

  • China ALMM equipment export policy decision due Nov 15

Risks ranked by holder concern

Capex guidance cut 53% (₹5,100 → ₹2,400 Cr)

High

Signals capital constraint or reprioritization away from original growth plan. Contradicts 10 GW ingot-wafer ambition and near-term BESS capex needs. If capex stays cut, growth velocity decelerates; if reinstated, it pressures near-term earnings and cash.

Margin compression from commodity inflation

High

OPM 28% vs. 29-30% guidance; transformer margin fell 22% → 12% Q1-Q2. New capacity is not generating operating leverage. Module BOM inflation (aluminum, copper, silicon, silver) ongoing; pricing power limited in commodity DCR segment.

QoQ profit decline despite revenue growth

High

PAT -2% QoQ vs. +6.9% revenue signals deleverage. Operating costs scaling with volume. Mix shift (higher-volume modules consuming cells; lower-margin business) not offset by cell line operating leverage. Profit momentum broken.

China ALMM export policy (Nov 15 decision)

Medium

Equipment export restrictions could delay or constrain ingot-wafer capex sourcing. Phase 1 (5 GW by Dec 2027) may slip. Impacts long-term ingot-wafer roadmap and capex timing. If ingot-wafer is deprioritized due to China policy, the growth narrative weakens further.

DCR module pricing deflation

Medium

DCR modules at ₹21-22/watt in highly competitive market; non-DCR pricing even lower. Pricing power limited. Near-term margin recovery depends on cost reduction, not price realization. Risk of competitive pricing collapse in next 2-3 years as Chinese capacity oversupply persists.

Inventory and working capital pressure

Medium

₹1.5% of sales inventory buildup due to cell line ramp and shipping delays. Temporary but reduces cash conversion and liquidity. If new capex is constrained and inventory doesn't convert to sales quickly, FCF pressure emerges.

How the street is positioned

The stock has repriced hard: ₹884 on Nov 11 is 36% below its all-time high of ₹1,388. It trades below its 20-day, 50-day, and 200-day moving averages — a bearish technical setup. RSI of 47.6 is neutral, not oversold, suggesting downside risk persists if fundamentals don't stabilize. Ownership reveals institutional conviction diverging from insider views. FII ownership rose 2.2pp QoQ to 7.92%, and DII rose 4.27pp to 17.97% — institutions are accumulating on weakness. But promoter ownership fell 5.37pp to 58.81%, revealing the founding family trimming. In May 2026, promoter-linked entities Jasveen Kaur Saluja and Charandeep Singh Saluja sold ~32.5 lakh shares at ₹955 per share — near the quarter's highs — while Edelweiss MF, Nomura, Tata MF, and HDFC MF bought aggressively. This divergence is a red flag: insiders distributed into strength; institutions accumulated into weakness. The capex cut and margin compression may have prompted the insider exit. The market is pricing near-term caution. The 36% drawdown from ATH, technical positioning below all key averages, and insider selling despite strong order book suggest the street has lost confidence in near-term execution.

What resolves this debate next (critical catalysts)
  • 1 · China ALMM policy (Nov 15)

    Government decision on ultra-thin wafer equipment exports will determine ingot-wafer capex feasibility and Phase 1 timeline (5 GW by Dec 2027). A ban or hard restriction forces Plan B (Taiwan sourcing, SE Asia alternatives) and delays capex. Clarity by Nov 15 is binary: green light or amber.

  • 2 · Cell line ramp and operating leverage (Dec 2026–Mar 2027)

    7 GW cell line to move from trial to 25-30% CUF in Dec and target 70% by March FY27. This is the profit inflection catalyst. If ramp hits target and cell margin realization improves from ₹0.12-0.14/watt to ₹0.16+, sequential profit will reaccelerate in Q3-Q4. If ramp stalls or margin remains under pressure, the profit decline is not temporary.

  • 3 · Q3–Q4 margin recovery (commodities reset)

    Transformer margin must normalize from 12% toward 15% as commodity cycle eases. Solar segment margin must hold 29-30%. If both stabilize and OPM recovers to 29%+, the capex cut becomes a near-term de-risking. If margins remain compressed or decline further, the capex cut signal a loss of pricing power or structural margin pressure.

  • 4 · BESS operationalization and regulatory clarity (Q2 FY28 and beyond)

    Battery Energy Storage launch in Q2 FY28 is critical for next-phase growth. Government KUSUM 2.0, Surya Ghar 2.0, and BESS subsidy/localization framework announcements pending. Early BESS profitability and order book will signal viability. If BESS ramps and government support materializes, a new growth vector emerges; if regulatory framework is unclear or demand softer than expected, BESS becomes a capex sink rather than a growth driver.

Premier Energies delivered the headline wins — revenue +43%, PAT +31%, order book +8% to ₹16,260 Cr. But the quarter is not a step-change in the story. QoQ profit fell 2% despite revenue growth, margins compressed under commodity pressure, and management slashed capex by 53%. The 7 GW cell line and 10 GW ingot-wafer roadmap remain compelling long-term; near-term execution risk is mounting.

The verdict: Hold. Premier is not broken — order book, capacity additions, and transformer/BESS diversification are real. But the capex cut signals caution on growth ambition, and profit momentum has stalled. Watch three things: (1) cell line ramp to 70% by March FY27 and margin realization; (2) transformer margin recovery to 15%+ as commodities reset; (3) China ALMM policy decision (Nov 15) on ingot-wafer sourcing. If cell ramp hits, margins stabilize, and capex is reinstated or BESS demand surprises on the upside, the -36% repricing may overshoot. If margins remain compressed, capex stays cut, or China policy restricts equipment, downside extends. Track organic EBITDA and operating margin as the lead indicators. Until margins recapture 29% and cell line hits 50%+ utilization, the stock likely trades in a hold range.

Informational and educational content only. Not investment advice.